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Cord blood transplantation(CBT) is an attractive alternative therapy in adult patients with advanced hematologicalmalignancies
in whom matched donors are unavailable. However, the risk of complications, especially infections, post-CBT increases the
mortality rates in these patients. Although the incidence of acute and chronic graft versus host disease (GVHD) post-CBT is
lower than that following bone marrow transplantation and peripheral blood stem cell transplantation (SCT), the additional
immunosuppressive therapy required to treat it could increase the mortality in these patients. Further, chronic GVHD following
CBT is milder and responds better to treatment than that occurring after bone marrow transplants. Unlike bone marrow
transplantation,the onsetof GVHD is a positive prognostic indicator of overallsurvival in patients receiving CBT, due to the graft
versus malignancy(GVM) eﬀect. This paper focuses on the immunereactions followingCBT and aimsto elucidate a management
strategy for acute and chronic GVHD.
1.Introduction
Cord blood transplantation (CBT) represents an attractive
alternative for patients with advanced hematological malig-
nancy who lack matched related or unrelated donors. Adult
patients receiving myeloablative or reduced-intensity CBT
display a 90% chance of engraftment, but also experience a
50% rate of transplant-related mortality, mostly attributable
to infection [1–6].
Unique manifestations of immune reactions that diﬀer
from those seen in conventional allogeneic stem cell trans-
plantation (allo-SCT) may occur after CBT. Fortunately,
the incidence and severity of acute graft-versus-host disease
(GVHD) after unrelated CBT are low compared with those
after allo-SCT from a matched unrelated or mismatched
family donor, despite infusion of human leukocyte antigen
(HLA)-mismatched graft [7, 8].
The clinical characteristics of patients with chronic
GVHD after CBT have not been well described. Studies deal-
ing with CBT have mainly focused on short-term events,
such as engraftment, acute GVHD, infections, and regimen-
related toxicities. Several groups have reported chronic
GVHD rates ranging from 17% to 89% [5, 6, 9–20]. How-
ever, studiesdealing with detailsofthe clinicalcharacteristics
of chronic GVHD, including the target organs, grading and
treatment response, are limited [5, 6, 9–20].
In this paper, I focus on the characteristics of immune
reactions following CBT, review the research performed to
date in Japan, Europe, and the United States, and attempt
to elucidate a management strategy that takes those clinical
characteristics into account.
2.EarlyImmune ReactionsandAcuteGVHD
2.1. Clinical Features. Posttransplant immune disorders, in-
cludingearly immune reactions and acuteGVHD,are poten-
tial complications following CBT in adult patients [1, 3,
21]. Such reactions and/or additional immunosuppressive
therapy might increase the risk of infection and organ
dysfunction, leading to high rates of transplantation-related
mortality.
Reportedly, the time course ofthe manifestations ofearly
immune reactions to CBT are unique.Aresearch groupfrom2 Stem Cells International
Japan ﬁrst classiﬁed early post-CBT immune reactions
according to the time course following CBT as: pre-en-
graftment immune reactions (PIR), engraftment syndrome
(ES), and acute GVHD (postengraftment immune reaction)
[1, 21, 22]. ES and acute GVHD has been reported in SCT
using bone marrow and peripheral blood stem cells, whereas
PIRhasnotbeenwelldescribed.PIRischaracterizedbyhigh-
gradefeverandweightgainanddevelopsatamedianofday9
post-CBT in approximately 80% patients [21]. The immune
reactions after CBT that were deﬁned in the study by Kishi
et al. [21] were used by another research group [23]. Accord-
ingtothem,whenfebrilepatients(bodytemperature ≥38◦C)
withnoevidenceofinfection oradverseeﬀectsofmedication
exhibited skin eruptions, diarrhea, jaundice (serum total
bilirubin >2.0mg/dL), or weight gain >10% of baseline,
these changes were deﬁned as immune reactions. Reactions
were classiﬁed into subtypes of pre-, peri-, and posten-
graftment reactions according to their timing of occurrence.
Immune reactions developing ≥6days before engraftment
were deﬁned as pre-engraftment immune reactions (PIRs),
while reactions within 5 days of engraftment were deﬁned as
engraftment syndrome (ES). Other reactions were deﬁned as
postengraftmentsyndrome,generallycorrespondingtoacute
GVHD.
The clinical features of PIR have been characterized in
both reduced-intensity conditioning CBT and myeloablative
CBT. [1, 21–25]. The incidence of PIR was relatively high
in studies from Japan where preparative regimen without
antithymocyte globulin (ATG) coupled with cyclosporine
alone as GVHD prophylaxis was mainly employed [22, 23,
26]. Thus, there is a possibility that insuﬃcient immune
suppression in CBT may play a role in the development of
PIR.
Some researchers have reported that the occurrence of
PIR depends on HLA disparities between recipient and cord
blood units [1, 21]. PIR supposedly develops in conjunction
with a cytokine storm or homeostasis-driven proliferation
of naive T cells [21, 27]. These immunological mechanisms
could be ameliorated in CBT with low HLA disparity.
However, associations between HLA disparity and the risk of
immune reactions in CBT remain unclear [9, 11, 12, 16, 28].
Previousstudieshavereportedalowerincidenceofsevere
acute GVHD despite commonly used HLA 1 or 2 antigen-
mismatched grafts in CBT compared with conventional allo-
SCT [5, 13, 29] .H o w e v e r ,t h es a m p l es i z e si nt h e s es t u d i e s
were small (18 to 562 patients) and the incidences of grade
II-IV acute GVHD varied widely from 26% to 51% [5, 6, 9–
13, 15–17, 30]. Hence, further large-scale studies on acute
GVHD after CBT are required. In addition, diﬀerencesin the
incidence of acute GVHD due to ethnicity, as in the case of
chronic GVHD [19], also need to be investigated.
From Western countries, PIR after double-unit cord
blood transplantation was reported [24, 25]. Recipients of
double cord blood units experience grade II acute GVHD
more frequently than single-unit recipients [24, 31], suggest-
ing the diﬀerence of underlying cytokine proﬁle. It is con-
ceivable that the immune interaction between the two units
may contribute to an enhanced immune reaction mediated
by eﬀector CD8+ T cells developing after CBT from naive
precursors. Considering that cord blood grafts contain ap-
proximately 1-logfewer T cells, the vast majority ofthose cell
are immunologically naive, there have been concernsregard-
ing the ability of cord blood-derived lymphocytes to mediate
graft-versus-malignancy eﬀects. However, the incidence of
leukemiarecurrence following CBT isnot diﬀerentfrom that
reported in recipients of bone marrow or peripheral blood
SCT. Moreover, leukemia patients in remission who received
myeloablative double unit CBT had less relapse rate [32].
Major or minor histocompatibility antigens expressed on
hematopoietic stem cells of the losing unit might be shared
by host leukemia cells, resulting in an enhanced graft-versus-
malignancy (GVM) eﬀects.
Brunstein et al. reported that KIR-ligand mismatch be-
tween the engrafted unit and the recipient had no favorable
outcomeintermsofacuteGVHD,transplant-related mortal-
ity, and survival [33]. Evenafterreduced intensity condition-
ing, KIR-L mismatch resulted in signiﬁcantly higher rates of
grade III-IV acute GVHD and transplant-related mortality
with inferior survival. Although ATG was incorporated
only in one-third of patients, one could hypothesize that
transplantation with KIR-L-mismatched CB units might
result in better clinical outcomes, based on the premise
that NK-cell alloreactivity dominates in the setting of low
graft T-cell numbers. It is possible that the in vivo T-
cell depletion secondary to ATG administration may have
contributed to favor GVM eﬀect in the presence of KIR-L
mismatch. However, the impact of ATG on the outcomes of
KIR-L-mismatched transplantations needstobeaddressedin
prospective studies.
2.2. Management of Early Immune Reactions. Optimal man-
agement of early immune reactions following CBT has
not been established. In CBT incorporating ATG, in which
immune reaction such as PIR or acute GVHD was reduced,
infection is a primary cause of death with profound T-cell
depletion in conjunction with delayed neutrophil recovery.
CBT without ATG is associated with a signiﬁcant risk of
GVHD, and serious infections remain a challenge, especially
in the setting of GVHD requiring systemic steroid. PIR itself
will induce organ failure such as organ toxicity in the severe
form [23], and the presence of PIR has been shown to cause
more NRM, thus, preventive strategy or early intervention
should be helpful [1].
It is to be noted that in several institute where more
potent immunosuppressive regimen is routinely incorpo-
rated early posttransplant, PIR is not a major clinical issue
after CBT [2, 13, 14, 34]. However, this does not warrant the
intensiﬁcation of immunosuppression for PIR like cortico-
steroids as preventative therapy after CBT, since there is
concern that there may be increased risk of infection or re-
lapse. Based on the experience of elderly patients who
received reduced-intensity CBT, high early mortality related
to PIR was substantially reduced by substituting Tacol-
imus for cyclosporine as GVHD prophylaxis [35]. Adding
methotrexate [23, 36] or mycophenolate mofetile [37]m a y
further improve the outcome. Recent study demonstrated
that the strategic delivery of posttransplantation high-doseStem Cells International 3
cyclophosphamide allows for the eﬀective deletion of prolif-
erating alloreactive cells in HLA-mismatched bone marrow
transplantation. Itmay bepostulatedthatcyclophosphamide
selectively kills cells reactive to abundant alloantigens while
minimally aﬀecting cells reactive to tumor-speciﬁc antigens,
and allowing the promotion of immunologic tolerance [38].
Although the type of graft is diﬀerent, a strong but short-
lived delivery of immune suppression may oﬀer beneﬁcial
eﬀect.
Once occurred, management of PIR in CBT is problem-
atic. It is reasonable thought that the therapeutic goal will
be immune suppression to an extent that PIR does not cause
organ dysfunction. Early recognition of PIR and treatment
withashort-coursecorticosteroidcanhelpavoidunnecessar-
ily long, empiric therapy that could promote opportunistic
infections. Treatment of acute GVHD is similar to the
treatment methods applied in the case of other grafts, such
as SCT using bone marrow or peripheral blood stem cells.
To the best of our knowledge, response to the treatment is
relatively good. As previously described [14], some grade II-
IV acute GVHD after CBT does not require systemic steroid
administration. This is particularly true in Japanese adult
CBT patients. In this regard, as well, it will be necessary to
carry out large-scale validation studies in the future.
3.ChronicGVHD
3.1. Clinical Features. Comparative studies on unrelated
bone marrow transplantation and CBT have shown that the
incidence of chronic GVHD is lower in the patients who
underwent CBT than those in bone marrow transplantation
[5, 13, 39]. However, most of the studies related to chronic
GVHD after CBT were small in scale and the reported
incidences of chronic GVHD have shown great variation
[5, 6, 9–18, 39–41]. The Japan Cord Blood Bank Network
researchonchronicGVHDin2008,whichisthelargeststudy
worldwide to date on this topic involved 1,072 patients [19].
In this large-scaled study, the incidence of post-CBT chronic
GVHD was 28%, showing that, in Japan, the incidence of
chronic GVHD following CBT is lower than the incidence
of chronic GVHD following unrelated bone marrow trans-
plantation[42, 43]. According to a recent report from Center
for International Blood and Marrow Transplant (CIBMT),
chronic GVHD was developedin 24% of patients, which was
signiﬁcantly lower compared with allele-matched peripheral
blood SCT, and matched bone marrow transplantation [44].
In this retrospective study, 72% of CBT recipients received
ATG. Regardless of graft source, the incidence of chronic
GVHD was lower in those treated with ATG as part of the
conditioning regimen. Thus, the result should be cautiously
interpreted. ATG can provide potent immunomodulation
and frequently incorporated towards improving transplant
outcome. However, the role of ATG in CBT is still under
debate.
Chronic GVHD following CBTis mild and responds well
totreatment, ashasbeenprovedbyearliersmall-scale studies
[10, 15–17, 40]a n dt h el a r g e - s c a l es t u d yfrom our group in
Japan [19]. The Japanese study found that the response rate
for chronic GVHD was 68%, while the mortality rate was a
mere 5% [19]. These rates are vastly superior to the compar-
ative rates for bone marrow transplantation and peripheral
blood SCT. These diﬀerences may contribute to favorable
long-term immune recovery following CBT. Alternatively,
mismatched unrelated cordbloodmay nothavethepotential
to fully reconstitute immune function, especially in adult
recipients.Theimpaired immunefunctionmaybeattributed
to decreased absoluteimmunocompetent cellsin cordblood,
disturbance of T-cell development in the host, reduced
thymic output, and defects in B-cell antibody production
[45, 46]. However, the diﬀerences inbasic mechanism of
immune reconstitution between CBT and SCT using bone
marrow orperipheral blood stem cellsremain unclearand in
need of further study.
In allogeneic SCT,the antitumor eﬀectderives from both
conditioning therapy prior to transplant and GVM eﬀect
arising from the attack of immunocompetent cells contained
in the graft on the host’s (patient’s) malignant cells. As has
been pointed out, in bone marrow transplantation, patients
who developmild chronic GVHD actually had a lowerrecur-
r e n c er a t ea n di m p r o v e do u t c o m e s[ 34, 47]. It was reported
that chronic GVHD following CBT is also accompanied by a
GVM eﬀect [19]. In this study, multivariate analysis showed
that the onset of chronic GVHD is a good prognostic factor
not only for the disease-free survival rate but also the overall
survival rate. At the same time, chronic GVHD was shown
to be a signiﬁcant factor in the prevention of recurrence
and progression of the disease. The ﬁnding that chronic
GVHD improveseventhe overall survival rate is noteworthy,
since it contrasts with what occurs with bone marrow
transplantation. In bone marrow transplantation, although
chronic GVHD prevents recurrence and progression of the
disease, some patients die due to the damages by chronic
GVHD. Thus, the chronic GVHD itself can, in the end, oﬀset
the GVM eﬀect, thus aﬀecting the overall survival rate and
the prognosis of the patient [34, 48, 49]. We surmise that
these contrasting results are due to the fact that chronic
GVHD following CBT is mild in severity compared to that
occurring after bone marrow transplantation.
In reduced-intensity conditioning (RIC) CBT, mild se-
verity of chronic GVHD observed in CBT may be translated
into less GVM eﬀect. In RIC-CBT, it was reported that
leukemia-free survival was decreased, and relapse incidence
was increased compared to those observed in myeloablative
CBT. The patients who underwent RIC-CBT with acute
myeloid leukemia in the second complete remission or the
ﬁrst complete remission duration <1 year had higher risk
of relapse and poorer leukemia-free survival with similar
incidence of chronic GVHD [50].
InJapan, ourstudygroup,theNagoyaBloodandMarrow
Transplantation Group, carried out a small-scale study [20]
on the clinical features of post-CBT chronic GVHD using
an NIH criteria [51] which is originally developed for bone
marrow transplantation and peripheral blood SCT. The
severity of chronic GVHD is classiﬁed as mild, moderate,
or severe on the basis of the target organ(s) and the clinical
features. This study analyzed the data of 29 patients who
survived for at least 100 days following CBT and found that4 Stem Cells International
chronicGVHD developedin 7patients, with thelimited type
occurring in 3 patients who had lesions that were limited
to part of the skin or only the liver, and the extensive type
occurring in 4 patients who had lesions in multiple organs
[20]. Using the NIH criteria, the chronic GVHD following
CBT w a sc l a s s i ﬁ e da sm i l di n6p a t i e n t s .T h eo n er e m a i n i n g
patient was classiﬁed as moderate GVHD. Thus, even by the
NIH classiﬁcation method, chronic GVHD following CBT
was mild in severity, and the prognosis was indicated to be
good.
3.2. Management of Chronic GVHD. Research [19, 20]c o n -
ductedin Japan indicates that chronic GVHD following CBT
hasalowerincidenceandismilderinseveritycomparedwith
chronic GVHD following bone marrow transplantation and
peripheralbloodSCT,thatitisalsoaccompaniedbyaclinical
GVM eﬀect and that the demand for therapeutic interven-
tion is lower than in the case of other grafts. Although, at
present, chronic GVHD following CBT is generally treated
by the same methods that were developed to manage
chronic GVHD following bone marrow transplantation and
peripheral blood SCT, it may be necessary to exercise
caution with the initiation, intensity, and duration. The NIH
evaluation method [51] may be a useful tool for making that
judgment. Accordingly, in order to establish a recommended
management system in the future, it will ﬁrst be necessary
to introduce the NIH’s diagnostic and evaluation criteria,
which are becoming ever more extensively used around the
world forothertransplantations, to theevaluationofchronic
GVHD following CBT. Since it would be impractical to
retrospectively rediagnose and reevaluate a large number of
patients using those methods, it will be desirable to begin
applying them to incoming patients. The data so generated
would, then, probably enable eﬀective investigation of the
treatment methods.
4.Conclusion
Post-CBT immune reactions are unique. The fact that the
clinical features of chronic GVHD, which is the major com-
plication during long-term survival after allogeneic trans-
plantation, are comparatively mild is very promising. If the
short-term safety of CBT with regard to early immune reac-
tions,andsoforth,thatarecurrentlyaspecialproblem,could
be improved, it would probably be possible to improve the
overall results of CBT, making it a promising treatment for
hematological diseases.
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